AB
KDNY

Amalgamated Bank’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Amalgamated Bank’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,310
Closed -$242K – 3043
2023
Q2 		$242K Buy
6,310
+1,038
+20% +$26.7K ﹤0.01% 1745
2023
Q1 		$122K Sell
5,272
-1,328
-20% -$31.7K ﹤0.01% 1975
2022
Q4 		$173K Buy
6,600
+158
+2% +$3.5K ﹤0.01% 1917
2022
Q3 		$127K Buy
6,442
+892
+16% +$17.9K ﹤0.01% 2040
2022
Q2 		$97K Buy
5,550
+845
+18% +$13.3K ﹤0.01% 2178
2022
Q1 		$77K Buy
+4,705
New +$64K ﹤0.01% 2300
2020
Q2 		– Sell
-2,247
Closed -$31K – 1689
2020
Q1 		$31K Buy
2,247
+28
+1% +$331 ﹤0.01% 1599
2019
Q4 		$13K Buy
2,219
+7
+0.3% +$38 ﹤0.01% 1838
2019
Q3 		$12K Sell
2,212
-20
-0.9% -$133 ﹤0.01% 1768
2019
Q2 		$17K Buy
+2,232
New +$34K ﹤0.01% 1793

Amalgamated Bank's KDNY Position: Q3 2023 in Review

Amalgamated Bank sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 6,310 shares — an estimated $242K sold.

Amalgamated Bank first reported a position in KDNY in Q2 2019 and held it in 10 quarters. The position peaked at $242K in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

  • Amalgamated Bank reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Amalgamated Bank sold 6,310 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $242K.
  • Amalgamated Bank first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2019 and held it in 10 quarters.
  • Amalgamated Bank's Chinook Therapeutics, Inc. Common Stock position peaked at $242K in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Amalgamated Bank's 13F filing for Q3 2023, filed 8 Nov 2023.